Results 21 to 30 of about 1,098,931 (194)

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI

Haematologica, 2018
Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyrosine kinase used in the treatment of B-cell malignancies. They bind irreversibly to cysteine 481 of Bruton tyrosine kinase, blocking autophosphorylation on tyrosine 223 and ...
Phillip L.R. Nicolson, Craig E. Hughes, Stephanie Watson, Sophie H. Nock, Alexander T. Hardy, Callum N. Watson, Samantha J. Montague, Hayley Clifford, Aarnoud P. Huissoon, Jean-Daniel Malcor, Mark R. Thomas, Alice Y. Pollitt, Michael G. Tomlinson, Guy Pratt, Steve P. Watson   +14 more
doaj   +1 more source

Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies

Journal of Hematology & Oncology, 2021
B cell receptor (BCR) signaling is involved in the pathogenesis of B cell malignancies. Activation of BCR signaling promotes the survival and proliferation of malignant B cells.
Danling Gu, Hanning Tang, Jiazhu Wu, Jianyong Li, Yi Miao   +4 more
doaj   +1 more source

Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor

Current Oncology, 2021
Bruton tyrosine kinase (BTK) inhibitors have become an important therapy for untreated and previously treated patients with chronic lymphocytic leukemia (CLL).
Omar Alkharabsheh, Alhareth Alsayed, Diana M. Morlote, Amitkumar Mehta   +3 more
doaj   +1 more source

Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A

Haematologica, 2019
Hemophilia A is a rare hemorrhagic disorder caused by the lack of functional pro-coagulant factor VIII. Factor VIII replacement therapy in patients with severe hemophilia A results in the development of inhibitory anti-factor VIII IgG in up to 30% of ...
Sandrine Delignat, Jules Russick, Bagirath Gangadharan, Julie Rayes, Mathieu Ing, Jan Voorberg, Srinivas V. Kaveri, Sébastien Lacroix-Desmazes   +7 more
doaj   +1 more source

“Double-Hit” Chronic Lymphocytic Leukemia, Involving the TP53 and MYC Genes

Frontiers in Oncology, 2022
Although the 17p deletion [del(17p)] is rare in cases of treatment-naive chronic lymphocytic leukemia (CLL), its frequency is higher in refractory/relapsed CLL – particularly in patients undergoing chemo(immuno)therapy.
Florence Nguyen-Khac, Florence Nguyen-Khac, Florence Nguyen-Khac   +2 more
doaj   +1 more source

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I [PDF]

, 2012
Background: Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase activity.
Ruimi, Nili, Martin Ruthardt, Mahajna, Jamal, Khateb, Mamduh, Jamal Mahajna, Ruthardt, Martin, Ottmann, Oliver G., Oliver Gerhard Ottmann, Mian, Afsar Ali, Nili Ruimi, Yousef Najajreh, Afsar Ali Mian, Ottmann, Oliver Gerhard, Susanne Badura, Metodieva, Anna, Najajreh, Yousef, Anna Metodieva, Mamduh Khateb, Badura, Susanne   +18 more
core   +2 more sources

Trafficking and signalling of oncogenic met [PDF]

, 2010
PhDThe Receptor Tyrosine Kinase (RTK) Met influences behaviour of several cancers by controlling growth, survival and metastasis. Recently, compartmentalisation of signals generated by RTKs, due to their endocytosis / trafficking, has emerged as a ...
Joffre, Carine
core   +4 more sources

Novel 5-Substituted Oxindoles Derivatives as Bruton\u27s Tyrosine Kinase Inhibitors: Design, Synthesis, Docking, Molecular Dynamic Simulation, and Biological Evaluation [PDF]

, 2023
Bruton\u27s tyrosine kinase (BTK) is a non-RTK cytoplasmic kinase predominantly expressed by haemopoietic lineages, particularly B-cells. A new Oxindole-based focused library was designed to identify potent compounds targeting the BTK protein as ...
Marián , Hajdúch, Vani Madhuri, Velavalapalli, Barbora , Lišková, Narendran, Annadurai, Rambabu , Gundla, Soňa ,, Gurská, Naresh Kumar, Katari, Venkatanarayana Chowdary, Maddipati, Viswanath, Das, Petr , Džubák   +9 more
core   +2 more sources

Combinatorial strategy using protein kinase inhibitors and a cytotoxic compound for highly resistant glioblastoma cells : "in vitro studies" [PDF]

, 2007
Glioblastoma multiforme (GBM) is the most frequent and the most aggesssive malignant neoplasm of the human central nervous system (CNS), with a median survival of less than one year. These neoplasms are radio- and chemo-resistant, and are highly invasive,
Failly, Mike
core   +1 more source

Response to therapy in Richter syndrome: a systematic review with meta-analysis of early clinical trials

Frontiers in Immunology, 2023
Introduction and aimsRichter syndrome (RS) represents the clonal evolution of chronic lymphocytic leukemia with histological transformation into a high-grade B cell lymphoma (diffuse large B cell lymphoma - DLBCL) or Hodgkin lymphoma. Considering that RS
Mário Sousa-Pimenta, Mário Sousa-Pimenta, Mário Sousa-Pimenta, Ângelo Martins, José Mário Mariz, Pedro Berraondo, Pedro Berraondo, Pedro Berraondo   +7 more
doaj   +1 more source